5-ht7 receptor antagonists
CA 2409729 A1 · Owner: Bristol-Myers Squibb Company · Inventors: Sun, Li-Qiang; Poss, Michael A.; Mattson, Ronald J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders depression, schizophrenia, anxiety, obsessive compulsive disorders circadian rhythm disorders, ocular , disorders and/or centrally and peripherally mediated hypertension are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 25, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 25, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 25, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.